CR11304A - Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal - Google Patents

Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal

Info

Publication number
CR11304A
CR11304A CR11304A CR11304A CR11304A CR 11304 A CR11304 A CR 11304A CR 11304 A CR11304 A CR 11304A CR 11304 A CR11304 A CR 11304A CR 11304 A CR11304 A CR 11304A
Authority
CR
Costa Rica
Prior art keywords
cns
methods
articles
administration
manufacture
Prior art date
Application number
CR11304A
Other languages
English (en)
Inventor
H Frey Ii William
Danielyan Lusine
H Gleiter Christoph
Original Assignee
H Frey Ii William
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Frey Ii William filed Critical H Frey Ii William
Publication of CR11304A publication Critical patent/CR11304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)

Abstract

Esta invencion se dirige, entre otras cosas, a la prevencion y/o al tratamiento del sistema nervioso central danado y/o en degeneracion debido a una enfermedad u otra condicion que causa la perdida o la muerte de las celulas del SNC.
CR11304A 2007-09-11 2010-03-09 Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal CR11304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97128407P 2007-09-11 2007-09-11
US12/109,066 US8283160B2 (en) 2007-09-11 2008-04-24 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Publications (1)

Publication Number Publication Date
CR11304A true CR11304A (es) 2010-05-03

Family

ID=40432083

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11304A CR11304A (es) 2007-09-11 2010-03-09 Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal

Country Status (24)

Country Link
US (3) US8283160B2 (es)
EP (1) EP2200621B1 (es)
JP (2) JP5600294B2 (es)
KR (2) KR101504110B1 (es)
CN (2) CN103181932A (es)
AT (1) ATE554778T1 (es)
AU (1) AU2008299124B2 (es)
BR (1) BRPI0816325B8 (es)
CA (1) CA2696892C (es)
CR (1) CR11304A (es)
CY (1) CY1113120T1 (es)
DK (1) DK2200621T3 (es)
ES (1) ES2388403T3 (es)
HR (1) HRP20120560T1 (es)
IL (1) IL204371A (es)
MX (1) MX2010002738A (es)
MY (1) MY154061A (es)
PL (1) PL2200621T3 (es)
PT (1) PT2200621E (es)
RU (1) RU2468818C2 (es)
SG (1) SG184724A1 (es)
SI (1) SI2200621T1 (es)
UA (1) UA98507C2 (es)
WO (1) WO2009035901A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518390B2 (en) * 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
EP3539380A3 (en) 2008-08-20 2019-12-18 Celularity, Inc. Improved cell composition and methods of making the same
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US9821149B2 (en) * 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
ES2676556T3 (es) 2011-12-23 2018-07-20 Depuy Synthes Products Llc Detección de células derivadas de tejido del cordón umbilical humano
US20130336928A1 (en) * 2012-06-18 2013-12-19 Healthpartners Research & Education Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s)
FR3001974B1 (fr) 2013-02-08 2016-02-12 Olivier Schussler Procede de purification de cellules
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10279012B2 (en) * 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
BR112015028605A8 (pt) 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
EP3114135A4 (en) * 2014-03-06 2018-01-24 Children's National Medical Center Treatment of neonatal brain injury with hb-egf
EP3174584B1 (en) * 2014-07-29 2022-05-04 Edenhoffer, Peter Positive pressure inspiration device for delivery of medicaments
US11413408B2 (en) 2014-07-29 2022-08-16 Peter Edenhoffer Positive pressure inspiration device for delivery of medicaments
US10130657B2 (en) 2015-02-13 2018-11-20 John C. Hughes Formulation, apparatus, and methods for treatment of brain trauma
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
US11559483B2 (en) * 2015-07-10 2023-01-24 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
BR112018002742B1 (pt) 2015-08-13 2023-05-16 Takeda Pharmaceutical Company Limited Tubo de coleta de sangue evacuado, método para a avaliação do nível endógeno de ativação do sistema de contato em um sujeito, método para a avaliação do nível de um fármaco visando o sistema de contato em um sujeito e método para a avaliação da imunogenicidade de um fármaco visando o sistema de contato
AU2017250298B2 (en) 2016-04-15 2024-10-03 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CN106924286A (zh) * 2017-02-16 2017-07-07 上海安集协康生物技术股份有限公司 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
CN108096280A (zh) * 2017-12-28 2018-06-01 上海安集协康生物技术股份有限公司 一种神经干细胞滴鼻剂
KR20220005900A (ko) * 2020-07-07 2022-01-14 가톨릭대학교 산학협력단 뇌신경계질환 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
ES2252993T3 (es) * 1998-12-09 2006-05-16 Chiron Corporation Administracion de agentes neurotroficos al sistema nervioso central.
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
JP3886346B2 (ja) * 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
CN101065478B (zh) * 2003-12-02 2012-07-04 塞拉维生物科学公司 用于繁殖神经祖细胞的组合物和方法
WO2007002664A2 (en) * 2005-06-22 2007-01-04 Massachusetts Institute Of Technology Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel
US9456979B2 (en) * 2006-04-27 2016-10-04 Sri International Adminstration of intact mammalian cells to the brain by the intranasal route
WO2008021196A2 (en) * 2006-08-09 2008-02-21 The Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Also Published As

Publication number Publication date
HRP20120560T1 (hr) 2012-08-31
US20160206554A1 (en) 2016-07-21
RU2468818C2 (ru) 2012-12-10
KR20150039197A (ko) 2015-04-09
MX2010002738A (es) 2010-08-04
SG184724A1 (en) 2012-10-30
JP5600294B2 (ja) 2014-10-01
DK2200621T3 (da) 2012-08-06
EP2200621B1 (en) 2012-04-25
US8283160B2 (en) 2012-10-09
IL204371A (en) 2015-02-26
EP2200621A1 (en) 2010-06-30
KR20100094450A (ko) 2010-08-26
BRPI0816325A2 (pt) 2015-03-24
PL2200621T3 (pl) 2012-10-31
PT2200621E (pt) 2012-07-31
CN101801397A (zh) 2010-08-11
EP2200621A4 (en) 2011-03-16
AU2008299124B2 (en) 2013-07-04
JP2010539084A (ja) 2010-12-16
ES2388403T3 (es) 2012-10-15
BRPI0816325B1 (pt) 2020-04-22
CA2696892A1 (en) 2009-03-19
KR101504110B1 (ko) 2015-03-19
US9445991B2 (en) 2016-09-20
MY154061A (en) 2015-04-30
ATE554778T1 (de) 2012-05-15
US20130028874A1 (en) 2013-01-31
US20090068155A1 (en) 2009-03-12
AU2008299124A1 (en) 2009-03-19
WO2009035901A1 (en) 2009-03-19
CA2696892C (en) 2016-05-17
CY1113120T1 (el) 2016-04-13
UA98507C2 (ru) 2012-05-25
RU2010113932A (ru) 2011-10-20
CN103181932A (zh) 2013-07-03
SI2200621T1 (sl) 2012-09-28
JP2014098051A (ja) 2014-05-29
BRPI0816325B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CR11304A (es) Metodos, composiciones farmaceuticas y articulos de manufactura para la administracion de celulas terapeuticas al sistema nervioso aniimal
PH12017501185A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
MA35431B1 (fr) Composition antiparasitaires comprenant un agent actif d'isoxazoline procedes et utilisations associes
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
BR112013001125A2 (pt) compostos inibidores de rho cinase bifuncionais, composição e uso
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
ATE555099T1 (de) Dual wirkende benzimidazol-derivate und deren verwendung als blutdrucksenkende mittel
BRPI0518282A2 (pt) uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
HK1135923A1 (en) Pharmaceutical agent having long-lasting effect of treating arthritic disorders
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2009038412A3 (en) Beta-secretase inhibiting compounds
MX340590B (es) Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CL2007003120A1 (es) Uso de una cantidad terapeuticamente eficaz de compuestos derivados de acido carbamico sustituidos y otro agente activo, para el tratamiento de la depresion.
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
MA32628B1 (fr) Agents antifongiques
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2010004859A (es) Nueva composicion para tratar los efectos secundarios del tratamiento anticanceroso.
WO2009038411A3 (en) Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety